FLASH TALKS SESSION
Long-term safety of garadacimab in patients with hereditary angioedema from the Phase 3 open-label extension study: An up to 3-year interim analysis
Presenting author: Dr Paul K. Keith
FLASH TALKS SESSION
The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States
Presenting author: Prof. Marc A. Riedl
FLASH TALKS SESSION
Attack-free probability modeling of garadacimab long-term prophylaxis for hereditary angioedema
Presenting author: Dr Philip H. Li